Pfiz­er bags an FDA OK for PARP play­er ta­la­zoparib — now the hard part be­gins

Pfiz­er has picked up an ap­proval for ta­la­zoparib, its PARP in­hibitor for a ge­net­i­cal­ly de­fined line of breast can­cer. And now the phar­ma play­er can …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.